Areas of focus
Approximately 1 in 8 women (13%) in the United States will develop breast cancer (BC) at some point in their life, making it the most common cancer diagnosed among women in the United States.3
With a deep understanding of the mechanism of the disease, and by listening and working with the patient community and those who care for them, we aspire to continue reimagining medicine for people touched by it.
Prostate cancer (PC) is the most common cancer among men, after skin cancer.4 At Novartis, we are focused on addressing the multi-faceted needs of people living with prostate cancer as they navigate this difficult disease.
Revolutionary therapies have transformed Chronic Myeloid Leukemia (CML), a type of blood cancer, into a chronic disease.5 However, many newly diagnosed patients do not meet their treatment goals and discontinue or change treatment due to intolerance.6 Patients need options that enable them to achieve meaningful outcomes while navigating a long-term, chronic illness.
Reimagining Cancer Care for the Next Generation Patient
We're witnessing a profound shift in how patients approach their cancer diagnosis and treatment. Learn more about what this means for the future.
The Novartis RLT Institute
RLT is an innovative approach to cancer treatment that delivers targeted ionizing radiation directly to tumor cells, regardless of where they are in the body. Novartis is committed to pursuing the potential of RLT.
Inspiring Generations to Prioritize their Breast Health
Early detection for breast cancer changes the game. Learn why at YourAttentionPlease.com.
Novartis Joins First-of-Its-Kind Breast Cancer Policy Coalition
Together with Susan G. Komen, we can drive meaningful change for generations of breast cancer patients to come through our coalition, the Alliance for Breast Cancer Policy.
Advancing Prostate Cancer Care: A Bold New Partnership
Prostate cancer is the second leading cause of cancer death in men in the United States⁷, but not all communities are impacted equally. In partnership with ZERO Prostate Cancer, we are reshaping cancer care for all.
Learn How Novartis is Connecting Patients to Pioneering Care at ASCO
Meeting the needs of the next generation patient requires fundamentally rethinking how we develop treatments and engage with patients. See the work we're doing in other key areas of oncology.
Other therapeutic areas
Cardiovascular, renal and metabolic
Discover how we are utilizing groundbreaking science, cutting-edge technology and strategic collaborations to help avoid preventable deaths and transform outcomes for people with cardiovascular, renal, and metabolic diseases.
Immunology
See how we are creating a world where health care professionals have more options and people living with immunological conditions can live their daily lives without limitations.
Neuroscience
Learn about our commitment to understanding and solving some of the most burdensome neurological conditions to improve the quality of life for patients and their caregivers, and to make a positive impact on society.
References
- Jianhui Zhao, Liying Xu, Jing Sun. et al. BMJ Oncology. 2023. doi: 2:e000049.2
- Kadambi S, Loh KP, Dunne R. et al. Nat Rev Clin Oncol. 2020 Dec;17(12):742- 755. doi: 10.1038/s41571-020-0421-z
- American Cancer Society. 2024.
- American Cancer Society. Assessed June 27, 2024. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html.
- Novartis, 2021. Accessed September 6, 2023. http://www.novartis.com/news/novartis-hematology-relentless-pursuit-cure
- Claudiani S, Chughtai F, Khan A. et al. Leukemia. 2024;38:796 - 802. doi:10.1038/s41375-024-02187-w
- Christoph Soerensen SJ, Montez-Rath ME, Chung BI. et al. MP68-08 Journal of Urology. 2024; 211(5S):e1110. doi:10.1097/01.JU.0001008744.60568.e8.08